193 related articles for article (PubMed ID: 35210118)
21. Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study.
Tawinprai K; Jungsomsri P; Pinijnai O; Tavonvunchai F; Lievjaroen A; Suwannaroj P; Siripongboonsitti T; Porntharukchareon T; Sornsamdang G; Ungtrakul T
Hum Vaccin Immunother; 2023 Dec; 19(1):2206360. PubMed ID: 37140889
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.
Costa Clemens SA; Jepson B; Bhorat QE; Ahmad A; Akhund T; Aley PK; Bansal H; Bibi S; Kelly EJ; Khan M; Lambe T; Lombaard JJ; Matthews S; Pipolo Milan E; Olsson U; Ramasamy MN; Moura de Oliveira Paiva MS; Seegobin S; Shoemaker K; Szylak A; Villafana T; Pollard AJ; Green JA;
Lancet Microbe; 2024 Jun; ():. PubMed ID: 38878794
[TBL] [Abstract][Full Text] [Related]
23. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Flaxman A; Marchevsky NG; Jenkin D; Aboagye J; Aley PK; Angus B; Belij-Rammerstorfer S; Bibi S; Bittaye M; Cappuccini F; Cicconi P; Clutterbuck EA; Davies S; Dejnirattisai W; Dold C; Ewer KJ; Folegatti PM; Fowler J; Hill AVS; Kerridge S; Minassian AM; Mongkolsapaya J; Mujadidi YF; Plested E; Ramasamy MN; Robinson H; Sanders H; Sheehan E; Smith H; Snape MD; Song R; Woods D; Screaton G; Gilbert SC; Voysey M; Pollard AJ; Lambe T;
Lancet; 2021 Sep; 398(10304):981-990. PubMed ID: 34480858
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
Lazarus R; Querton B; Corbic Ramljak I; Dewasthaly S; Jaramillo JC; Dubischar K; Krammer M; Weisova P; Hochreiter R; Eder-Lingelbach S; Taucher C; Finn A;
Lancet Infect Dis; 2022 Dec; 22(12):1716-1727. PubMed ID: 36075233
[TBL] [Abstract][Full Text] [Related]
25. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
26. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults.
Assantachai P; Niyomnaitham S; Chatthanawaree W; Intalapaporn S; Muangpaisan W; Phannarus H; Saichompoo RB; Sura-Amonrattana U; Wongprompitak P; Toh ZQ; Licciardi PV; Srisutthisamphan K; Chokephaibulkit K
J Infect Dis; 2023 Oct; 228(7):868-877. PubMed ID: 37141388
[TBL] [Abstract][Full Text] [Related]
28. Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.
Garg S; Thongcharoen P; Praphasiri P; Chitwarakorn A; Sathirapanya P; Fernandez S; Rungrojcharoenkit K; Chonwattana W; Mock PA; Sukwicha W; Katz JM; Widdowson MA; Curlin ME; Gibbons RV; Holtz TH; Dawood FS; Olsen SJ
Clin Infect Dis; 2016 Feb; 62(3):383-391. PubMed ID: 26486702
[TBL] [Abstract][Full Text] [Related]
29. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
Falsey AR; Sobieszczyk ME; Hirsch I; Sproule S; Robb ML; Corey L; Neuzil KM; Hahn W; Hunt J; Mulligan MJ; McEvoy C; DeJesus E; Hassman M; Little SJ; Pahud BA; Durbin A; Pickrell P; Daar ES; Bush L; Solis J; Carr QO; Oyedele T; Buchbinder S; Cowden J; Vargas SL; Guerreros Benavides A; Call R; Keefer MC; Kirkpatrick BD; Pullman J; Tong T; Brewinski Isaacs M; Benkeser D; Janes HE; Nason MC; Green JA; Kelly EJ; Maaske J; Mueller N; Shoemaker K; Takas T; Marshall RP; Pangalos MN; Villafana T; Gonzalez-Lopez A;
N Engl J Med; 2021 Dec; 385(25):2348-2360. PubMed ID: 34587382
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and reactogenicity of repeated intradermal mRNA COVID-19 vaccines administered as a second booster dose in a Thai geriatric population.
Assantachai P; Niyomnaitham S; Toh ZQ; Thammasalee M; Pengsorn N; Monklang W; Licciardi PV; Chokephaibulkit K
Front Immunol; 2023; 14():1302041. PubMed ID: 38274835
[TBL] [Abstract][Full Text] [Related]
31. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial.
Madhavan M; Ritchie AJ; Aboagye J; Jenkin D; Provstgaad-Morys S; Tarbet I; Woods D; Davies S; Baker M; Platt A; Flaxman A; Smith H; Belij-Rammerstorfer S; Wilkins D; Kelly EJ; Villafana T; Green JA; Poulton I; Lambe T; Hill AVS; Ewer KJ; Douglas AD
EBioMedicine; 2022 Nov; 85():104298. PubMed ID: 36229342
[TBL] [Abstract][Full Text] [Related]
32. Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population.
Sirisreetreerux S; Porntharukchareon T; Dechates B; Rangsrisaeneepitak V; Therawit P; Worawitchawong S; Sornsamdang G; Soonklang K; Tawinprai K
Sci Rep; 2023 Jul; 13(1):11798. PubMed ID: 37479776
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.
Wanlapakorn N; Suntronwong N; Phowatthanasathian H; Yorsaeng R; Thongmee T; Vichaiwattana P; Auphimai C; Wongsrisang L; Klinfueng S; Sudhinaraset N; Poovorawan Y
Vaccine; 2022 May; 40(23):3203-3209. PubMed ID: 35465981
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.
Zeng G; Wu Q; Pan H; Li M; Yang J; Wang L; Wu Z; Jiang D; Deng X; Chu K; Zheng W; Wang L; Lu W; Han B; Zhao Y; Zhu F; Yu H; Yin W
Lancet Infect Dis; 2022 Apr; 22(4):483-495. PubMed ID: 34890537
[TBL] [Abstract][Full Text] [Related]
35. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions.
Lee SW; Moon JY; Lee SK; Lee H; Moon S; Chung SJ; Yeo Y; Park TS; Park DW; Kim TH; Sohn JW; Yoon HJ; Kim SH
Front Immunol; 2021; 12():779212. PubMed ID: 34899739
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial.
Asano M; Okada H; Itoh Y; Hirata H; Ishikawa K; Yoshida E; Matsui A; Kelly EJ; Shoemaker K; Olsson U; Vekemans J
Int J Infect Dis; 2022 Jan; 114():165-174. PubMed ID: 34688944
[TBL] [Abstract][Full Text] [Related]
37. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study.
Niyomnaitham S; Chatsiricharoenkul S; Toh ZQ; Senawong S; Pheerapanyawaranun C; Phumiamorn S; Licciardi PV; Chokephaibulkit K
Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146575
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial.
Li JX; Wu SP; Guo XL; Tang R; Huang BY; Chen XQ; Chen Y; Hou LH; Liu JX; Zhong J; Pan HX; Shi FJ; Xu XY; Li ZP; Zhang XY; Cui LB; Tan WJ; Chen W; Zhu FC;
Lancet Respir Med; 2022 Aug; 10(8):739-748. PubMed ID: 35605625
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
Frenck RW; Belshe R; Brady RC; Winokur PL; Campbell JD; Treanor J; Hay CM; Dekker CL; Walter EB; Cate TR; Edwards KM; Hill H; Wolff M; Leduc T; Tornieporth N
Vaccine; 2011 Aug; 29(34):5666-74. PubMed ID: 21699951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
